<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OALibJ</journal-id><journal-title-group><journal-title>Open Access Library Journal</journal-title></journal-title-group><issn pub-type="epub">2333-9705</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oalib.1101593</article-id><article-id pub-id-type="publisher-id">OALibJ-68423</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Business&amp;Economics</subject><subject> Chemistry&amp;Materials Science</subject><subject> Computer Science&amp;Communications</subject><subject> Earth&amp;Environmental Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject><subject> Social Sciences&amp;Humanities</subject></subj-group></article-categories><title-group><article-title>
 
 
  Adherence to American Association for the Study of Liver Diseases (AASLD) Guidelines and Predictors of Readmission in Cirrhotic Patients: A Single Center Experience
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Maen</surname><given-names>M. Masadeh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ali</surname><given-names>Zaied</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Feroze</surname><given-names>Hussain</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Heidi</surname><given-names>Spratt</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Roger</surname><given-names>Soloway</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Gastroenterology and Hepatology, University of Texas Medical Branch at Galveston, Galveston, USA</addr-line></aff><aff id="aff3"><addr-line>Department of Biochemistry and Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, USA</addr-line></aff><aff id="aff1"><addr-line>Department of Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, USA</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>maen_masadeh@hotmail.com(MMM)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>06</month><year>2015</year></pub-date><volume>02</volume><issue>06</issue><fpage>1</fpage><lpage>8</lpage><history><date date-type="received"><day>13</day>	<month>May</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>28</month>	<year>May</year>	</date><date date-type="accepted"><day>4</day>	<month>June</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Introduction: Liver cirrhosis (LC) is a major cause of mortality and morbidity in the United States. American Association for the Study of Liver Disease (AASLD) has developed guidelines for the management of patients with LC. Methods: We conducted a one-year retrospective chart review study of patients admitted with LC related complication. Our primary outcome was adherence to AASLD guidelines for the management of variceal bleeding (VB), fluid overload and hepatocellular carcinoma (HCC) screening, and secondary outcome was re-admission rate within 30 days of discharge. Results: A total of 139 patients were reviewed. Majority were males (65%) and Caucasians (65%). The admission indication was mainly for fluid overload (39%), hepatic encephalopathy (36%) and VB (27%). The one-month readmission rate was 31%, of those 47% and 37% were admitted for hepatic encephalopathy and fluid overload respectively. Periodic screening for HCC was done in only 40% of patients. Ninety-five percent of patients admitted with VB received PPI, octreotride and antibiotics. Diet education was only documented in 9% of patients on discharge. Significant predictors for 30-day readmission included high MELD score, elevated creatinine, and taking diuretics/lactulose before hospitalization in addition to shorter length of stay. Conclusion: Compliance with AASLD guidelines was optimal for patients with VB. Further optimization is required for HCC screening and patient education. Multiple factors play a role in readmissions for patients with cirrhosis; this model helps to identify patients at risk for readmission and opens an area for quality improvement measures to avoid unnecessary hospitalizations. 
  
 
</p></abstract><kwd-group><kwd>Liver Cirrhosis</kwd><kwd> Readmission</kwd><kwd> Hepatic Encephalopathy</kwd><kwd> Ascites</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Liver cirrhosis (LC) is a major cause of mortality and morbidity in the United States. More than 100,000 patients are discharged each year with chronic liver disease and cirrhosis as the first-listed diagnosis [<xref ref-type="bibr" rid="scirp.68423-ref1">1</xref>] . It is the 12th leading cause of death in adults in the United States. It results in 31,903 deaths per year with 10.3 deaths per 100,000 population [<xref ref-type="bibr" rid="scirp.68423-ref2">2</xref>] .</p><p>Liver fibrosis results from the perpetuation of the normal wound healing response resulting in an abnormal continuation of fibrogenesis (connective tissue production and deposition). Fibrosis progresses at variable rates depending on the cause of liver disease, environmental and host factors [<xref ref-type="bibr" rid="scirp.68423-ref3">3</xref>] . Cirrhosis is frequently indolent, asymptomatic and unsuspected until complications of liver disease present. However, initial clinical presentation of patients with decompensated cirrhosis is still common and is characterized by the presence of dramatic and life-threatening complications, such as variceal hemorrhage, ascites, spontaneous bacterial peritonitis, or hepatic encephalopathy [<xref ref-type="bibr" rid="scirp.68423-ref3">3</xref>] . Radiological diagnosis of liver cirrhosis can be challenging as ultrasonography, computerized tomography and magnetic resonance imaging are not sensitive to detect cirrhosis, and final diagnosis still relies on histology. However, their specificity is high when an obvious cause is present and imaging reveals an inhomogeous hepatic texture or surface, rarefied hepatic central vein, an enlarged caudate lobe, splenomegaly or collateral veins [<xref ref-type="bibr" rid="scirp.68423-ref4">4</xref>] .</p><p>Ascites is the most common major complication of cirrhosis; other major complications include: hepatic encephalopathy (HE) and variceal hemorrhage [<xref ref-type="bibr" rid="scirp.68423-ref5">5</xref>] . The mainstays of treatment of LC patients with ascites include patient education regarding dietary sodium restriction (2000 mg/day [88 mmol/day]) and oral diuretics [<xref ref-type="bibr" rid="scirp.68423-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.68423-ref7">7</xref>] .</p><p>Variceal bleeding is considered the most dangerous and life threatening consequence of portal hypertension [<xref ref-type="bibr" rid="scirp.68423-ref8">8</xref>] . Management of suspected acute variceal bleeding includes: adequate resuscitation with airway protection &amp; acceptable volume support, somatostatin analogues (to be continued for 3 - 5 days once varices are proven), short-term (5 - 7 days) prophylactic antibiotic therapy and Esophagogastroduodenoscopy as soon as possible to confirm the diagnosis and implement endoscopic therapy [<xref ref-type="bibr" rid="scirp.68423-ref9">9</xref>] .</p><p>Primary liver cancer (hepatocellular carcinoma, HCC) is a serious late complication of chronic hepatic injury, particularly in cirrhosis due to Hepatitis B Virus, Hepatitis C Virus, and hemochromatosis. The incidence of HCC has increased by 70% in the United States over the past 20 years, particularly among younger patients [<xref ref-type="bibr" rid="scirp.68423-ref10">10</xref>] , Biannual screening for HCC by alpha fetoprotein testing and ultrasound has shown to reduce mortality [<xref ref-type="bibr" rid="scirp.68423-ref11">11</xref>] .</p><p>Hospital readmissions among patients with decompensated liver cirrhosis are common, costly, moderately predictable―in some cases possibly preventable―and independently associated with mortality [<xref ref-type="bibr" rid="scirp.68423-ref12">12</xref>] . Multiple factors are thought to play a role like nursing, system, physician and not less significant patients’ factors. Managing patients with liver cirrhosis decompensated by variceal bleeding, ascites or hepatic encephalopathy by following AASLD guidelines would optimize care and subsequently lead to significant decrease in morbidity and mortality [<xref ref-type="bibr" rid="scirp.68423-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.68423-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.68423-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.68423-ref13">13</xref>] .</p><p>The aim of this study was to evaluate the adherence to AASLD guidelines at a tertiary teaching center and to assess for predictors of re-hospitalization within 30 days after discharge.</p></sec><sec id="s2"><title>2. Methods</title><p>We conducted a retrospective chart review for patients with decompensated LC admitted to University of Texas Medical Branch (UTMB) at Galveston from June 2012 to June 2013. Cases were identified using International Classification of Diseases, 9th revision (ICD-9) codes: 571.2 (alcoholic cirrhosis), 571.5 (non-alcoholic cirrhosis), 572.3 (portal hypertension), 572.2 (hepatic encephalopathy), 456.0 to 456.2 (esophageal varices with and without bleeding), 789.5 (ascites), 789.59 (nonmalignant ascites), 567.23 (spontaneous bacterial peritonitis), and 572.4 (hepatorenal syndrome). Electronic medical records were reviewed by the authors MM and AZ. Liver cirrhosis was confirmedeither by histology if liver biopsy was done and showed grade 4 fibrosis, or by imaging if ultrasound (US), Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) showed typical features of advanced liver disease; recanalization of umbilical vein, nodularity of the liver, presence of vascular collaterals and reversal of portal blood flow. We included patients with LC who were admitted for: fluid overload, HE, variceal bleeding, hepatorenal syndrome, SBP or abdominal pain. We excluded patients who were admitted for any other reasons including infection other than SBP, patients who left the hospital against medical advice and hospice patients. For patients with multiple admissions, the latest admission that meets the inclusion criteria was included.</p><sec id="s2_1"><title>2.1. Outcome</title><p>Our primary outcome was adherence to AASLD guidelines for the management of variceal hemorrhage, fluid overload and hepatocellular carcinoma screening. Adherence to AASLD guidelines for the management of variceal hemorrhage was defined as: use of proton pump inhibitor, somatostatin analogues and antibiotic therapy for SBP prophylaxis at the time of admission. Adherence to AASLD guidelines for the management of fluid overload was defined as: use of diuretics, salt restriction and patient education. Adherence to AASLD guidelines for the screening of HCC was defined as: Liver ultrasound or CT scan every 6 - 12 months. Our secondary outcome was re-admission rate within 30 days of discharge with the exclusion of elective admissions.</p></sec><sec id="s2_2"><title>2.2. Date Collection</title><p>Study data were collected and managed using REDCap electronic data capture tools hosted at UTMB [<xref ref-type="bibr" rid="scirp.68423-ref14">14</xref>] . REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources.</p><p>The institutional review board (IRB) approved our study. Variables collected include demographics (age, sex, and race), etiology of cirrhosis, and presence of hepatocellular carcinoma, comorbid conditions and reason for hospitalization. Laboratory values of interest included white blood cell count, platelet count, sodium level, creatinine level, albumin level, total bilirubin, and international normalized ratioon admission. Model for End-stage Liver Disease (MELD) score and Child’s Pugh score were both calculated. Data regarding whether the patient required intensive level of care or was readmitted within 30 days of discharge was also gathered.</p></sec><sec id="s2_3"><title>2.3. Statistical Analysis</title><p>Descriptive statistics was conducted using STATA software for the primary outcome. For the secondary outcome Multivariate Adaptive Regression Splines (MARS) model was developed on 80% of the data (training), and tested on the remaining 20% (testing). MARS is a nonparametric regression procedure that seeks to create a classification model based on piecewise linear regressions. This algorithm has the ability to search through a large number of candidate predictor variables to determine those most relevant to the classification model. We used five variables as input, and created a model with the ability to correctly predict hospital readmission with an 81.2% success rate in the training population and a 72.73% success rate in the testing population based on these five variables.</p></sec></sec><sec id="s3"><title>3. Results</title><p>A total of 139 patients met the inclusion criteria. The baseline characteristics of these patients are summarized in <xref ref-type="table" rid="table1">Table 1</xref>. The majority of patients were males (64.8%) and Caucasians (65.5%). The most common etiologies of LC were alcoholic liver disease (61.2%), hepatitis C virus infection (49.6%) and fatty liver disease (7.9%) while other etiologies like autoimmune hepatitis, Hemochromatosis and primary biliary cirrhosis made less than 10%. The indication for admission included fluid overload (38.9%), HE (36.0%), variceal bleeding (26.6%), abdominal pain (11.5%), SBP (5.0%) and coagulopathy (2.9%).</p><p>One third of patients required Intensive Care Unit (ICU) level of care. A hepatologist, either as a consult service or as a primary service, was involved in 84.2% of patients’ care. Only 31% of patients followed up with hepatology or gastroenterology clinic within 1 month after discharge. Physical exam findings and laboratory values on presentation are shown in <xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="table" rid="table3">Table 3</xref> respectively.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Baseline characteristics of the patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >N = 139</th></tr></thead><tr><td align="center" valign="middle" >Age<sup>-</sup>year</td><td align="center" valign="middle" >54.6 &#177; 9.9</td></tr><tr><td align="center" valign="middle" >Male sex―n. (%)</td><td align="center" valign="middle" >90 (64.8)</td></tr><tr><td align="center" valign="middle" >Race―n. (%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >African American</td><td align="center" valign="middle" >16 (11.5)</td></tr><tr><td align="center" valign="middle" >Caucasian</td><td align="center" valign="middle" >91 (65.5)</td></tr><tr><td align="center" valign="middle" >Hispanic</td><td align="center" valign="middle" >32 (23.0)</td></tr><tr><td align="center" valign="middle" >Etiology of cirrhosis―n. (%)<sup>*</sup></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >HCV</td><td align="center" valign="middle" >69 (49.6)</td></tr><tr><td align="center" valign="middle" >Alcohol</td><td align="center" valign="middle" >86 (61.2)</td></tr><tr><td align="center" valign="middle" >HBV</td><td align="center" valign="middle" >2 (1.4)</td></tr><tr><td align="center" valign="middle" >NAFLD</td><td align="center" valign="middle" >11 (7.9)</td></tr><tr><td align="center" valign="middle" >Autoimmune</td><td align="center" valign="middle" >6 (4.3)</td></tr><tr><td align="center" valign="middle" >Other<sup>†</sup></td><td align="center" valign="middle" >9 (6.5)</td></tr><tr><td align="center" valign="middle" >Reason for admission―n. (%)<sup>*</sup></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Variceal Bleeding</td><td align="center" valign="middle" >37 (26.6)</td></tr><tr><td align="center" valign="middle" >Ascites</td><td align="center" valign="middle" >54 (38.9)</td></tr><tr><td align="center" valign="middle" >Hepatic Encephalopathy</td><td align="center" valign="middle" >50 (36.0)</td></tr><tr><td align="center" valign="middle" >Coagulopathy</td><td align="center" valign="middle" >4 (2.9)</td></tr><tr><td align="center" valign="middle" >SBP</td><td align="center" valign="middle" >7 (5.0)</td></tr><tr><td align="center" valign="middle" >Abdominal Pain</td><td align="center" valign="middle" >16 (11.5)</td></tr><tr><td align="center" valign="middle" >Other<sup>‡</sup></td><td align="center" valign="middle" >12 (8.6)</td></tr><tr><td align="center" valign="middle" >Hepatologist involved in patients’ care―n. (%)<sup>&#167;</sup></td><td align="center" valign="middle" >117 (84.2)</td></tr><tr><td align="center" valign="middle" >30 day re-admission―n. (%)</td><td align="center" valign="middle" >43 (31.0)</td></tr><tr><td align="center" valign="middle" >Procedures―n. (%)<sup>*</sup></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Paracentesis</td><td align="center" valign="middle" >54 (38.9)</td></tr><tr><td align="center" valign="middle" >EGD</td><td align="center" valign="middle" >45 (32.3)</td></tr><tr><td align="center" valign="middle" >Colonoscopy</td><td align="center" valign="middle" >5 (3.6)</td></tr><tr><td align="center" valign="middle" >TIPS</td><td align="center" valign="middle" >6 (4.3)</td></tr><tr><td align="center" valign="middle" >Liver Biopsy</td><td align="center" valign="middle" >3 (2.2)</td></tr><tr><td align="center" valign="middle" >ICU level of care―n. (%)</td><td align="center" valign="middle" >46 (33.1)</td></tr><tr><td align="center" valign="middle" >Mortality―n. (%)</td><td align="center" valign="middle" >12 (8.6)</td></tr><tr><td align="center" valign="middle" >Comorbidity―n. (%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Heart Disease</td><td align="center" valign="middle" >16 (11.5)</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" >27 (19.4)</td></tr><tr><td align="center" valign="middle" >Renal Failure<sup>&#182;</sup></td><td align="center" valign="middle" >44 (31.7)</td></tr><tr><td align="center" valign="middle" >COPD</td><td align="center" valign="middle" >5 (3.6)</td></tr><tr><td align="center" valign="middle" >HIV</td><td align="center" valign="middle" >2 (1.4)</td></tr><tr><td align="center" valign="middle" >Malignancy<sup>‖</sup></td><td align="center" valign="middle" >35 (25.2)</td></tr></tbody></table></table-wrap><p><sup>*</sup>Patients may have more than one reason to be admitted, etiology of cirrhosis or procedure performed. <sup>†</sup>Include: Hemochromatosis (1), Wilson Disease (0), PBC (2), PSC (1), Alpha 1 Anti Trypsin Deficiency (1), Secondary Liver Cancer (1) and Cryptogenic (3). <sup>‡</sup>Include: AKI, Alcoholic hepatitis, Cholangitis, HCC, Hepatic hydrothorax, Jaundice, Umbilical hernia. <sup>&#167;</sup>Either as admitted to liver service or as a consult service when admitted to non-liver service. <sup>&#182;</sup>Includes: AKI (30), CKD (9) and ESRD (5). <sup>‖</sup>Includes HCC (22) and other (13). Abbreviations: HCV: Hepatitis C Virus; HBV: Hepatitis B Virus; NAFLD: Non Alcoholic Fatty Liver Disease; PBC: Primary Biliary Cirrhosis; PSC: Primary Sclerosing Cholangitis; AKI: Acute Kidney Injury; CKD: Chronic Kidney Disease; ESRD: End Stage Renal Disease; HCC: Hepatocellular Cancer; EGD: Esophagogastroduodenoscopy; TIPS: Transjugular Intrahepatic Portosystemic Shunt; ICU: Intensive Care Unit; COPD: Chronic Obstructive Pulmonary Disease; HIV: Human Immunodeficiency Virus</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Physical examination findings of the patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >N = 139</th></tr></thead><tr><td align="center" valign="middle" >Systolic Blood Pressure &gt; 100 mm Hg―n. (%)</td><td align="center" valign="middle" >122 (87.8)</td></tr><tr><td align="center" valign="middle" >Heart Rate, rate/min―n. (%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;50</td><td align="center" valign="middle" >4 (2.9)</td></tr><tr><td align="center" valign="middle" >50 - 59</td><td align="center" valign="middle" >4 (2.9)</td></tr><tr><td align="center" valign="middle" >60 - 99</td><td align="center" valign="middle" >87 (62.6)</td></tr><tr><td align="center" valign="middle" >≥100</td><td align="center" valign="middle" >44 (31.4)</td></tr><tr><td align="center" valign="middle" >Mental Status―n. (%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Alert</td><td align="center" valign="middle" >99 (71.2)</td></tr><tr><td align="center" valign="middle" >Disoriented</td><td align="center" valign="middle" >20 (14.4)</td></tr><tr><td align="center" valign="middle" >Stuporous</td><td align="center" valign="middle" >13 (9.4)</td></tr><tr><td align="center" valign="middle" >Comatose</td><td align="center" valign="middle" >7 (5.0)</td></tr><tr><td align="center" valign="middle" >Flapping Tremor―n. (%)</td><td align="center" valign="middle" >24 (17.3)</td></tr><tr><td align="center" valign="middle" >Ascites―n. (%)</td><td align="center" valign="middle" >81 (58.3)</td></tr><tr><td align="center" valign="middle" >Bilateral Lower Extremity Edema―n. (%)</td><td align="center" valign="middle" >68 (49.0)</td></tr><tr><td align="center" valign="middle" >Jaundice―n. (%)</td><td align="center" valign="middle" >56 (40.3)</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Laboratory results of the patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Value (&#177;SD)</th></tr></thead><tr><td align="center" valign="middle" >Hgb, g/dL</td><td align="center" valign="middle" >10.3 (&#177;2.3)</td></tr><tr><td align="center" valign="middle" >WBC count, 10<sup>6</sup> cells/dL</td><td align="center" valign="middle" >8.0 (&#177;5.2)</td></tr><tr><td align="center" valign="middle" >Platelet count, 10<sup>3</sup> cells/&#181;L</td><td align="center" valign="middle" >120 (&#177;86)</td></tr><tr><td align="center" valign="middle" >INR</td><td align="center" valign="middle" >1.8 (&#177;2.0)</td></tr><tr><td align="center" valign="middle" >Albumin, g/dL</td><td align="center" valign="middle" >2.8 (&#177;0.6)</td></tr><tr><td align="center" valign="middle" >Total Bilirubin, U/L</td><td align="center" valign="middle" >4.9 (&#177;6.8)</td></tr><tr><td align="center" valign="middle" >Sodium, mEq/L</td><td align="center" valign="middle" >136 (&#177;6)</td></tr><tr><td align="center" valign="middle" >Potassium, mEq/L</td><td align="center" valign="middle" >4.3 (&#177;0.8)</td></tr><tr><td align="center" valign="middle" >Creatinine, mg/dL</td><td align="center" valign="middle" >1.4 (&#177;1.4)</td></tr><tr><td align="center" valign="middle" >MELD score</td><td align="center" valign="middle" >18 (&#177;8)</td></tr><tr><td align="center" valign="middle" >Child Pugh Score</td><td align="center" valign="middle" >9 (&#177;2)</td></tr></tbody></table></table-wrap><p>Abbreviations: SD: Standard Deviation; Hgb: Hemoglobin; WBC: White Blood Cell; INR: International Normalized Ratio; MELD: Model for End Stage Liver Disease.</p><p>For patients admitted with fluid overload (n = 54), 31.7% of them were diuretics na&#239;ve, and dose adjustment</p><p>on discharge was done in 57.6%. Eighty seven percent of them were discharged on low sodium diet but patient education was only documented in 7.4%.</p><p>For patients admitted with variceal bleeding (n = 37), prior to admission screening esophagogastroduodenoscopy was done in 74.8% of them. Proton pump inhibitors, octreotide and SBP prophylaxis were given on admissionto 94.6% of patients.</p><p>Hepatocellular cancer screening modalities included liver ultrasound (manufacturer General Electric) (56.1%), CT (manufacturer General Electric) with triple phase contrast (62.6%) and MRI (manufacturer General Electric) of the liver (6.5%). For patients who are eligible for HCC screening, interval screening every 6 to 12 months was done in only 40.3%.Primary study outcomes are summarized in <xref ref-type="table" rid="table4">Table 4</xref>.</p><p>Thirty-day readmission rate was 31.0%, of those 47% and 37% were admitted for HE and fluid overload respectively. Significant predictors for 30-day readmission included high MELD score and elevated creatinine. These results are similar to results found by Volk et al. [<xref ref-type="bibr" rid="scirp.68423-ref12">12</xref>] . Also, Patients who were taking diuretics and/or lactulose before hospitalization were found more likely to be readmitted. Average length of stay (LOS) was 5.2 days, and patients with a shorter LOS were more likely to be readmitted. Etiology of cirrhosis, reason for admission and Child Pugh score were not found to be important predictors. The Multivariate adaptive regression splines (MARS) model predicted 30-day readmission with an area under the receiver operating characteristic curve of 0.87 and 0.74 in the training and testing data respectively with a y-value of 0.6 (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s4"><title>4. Discussion</title><p>Patients with chronic liver disease presenting with acute decompensation are often seriously ill. The AASLD proposed guidelines for the management of such events like variceal bleeding [<xref ref-type="bibr" rid="scirp.68423-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.68423-ref13">13</xref>] and ascites and fluid over load [<xref ref-type="bibr" rid="scirp.68423-ref15">15</xref>] . Guidelines were also proposed for HCC screening [<xref ref-type="bibr" rid="scirp.68423-ref16">16</xref>] . In this study we evaluated the adherence to standard of care for these patients. Despite the presence of evidence for best practice for patients with ascites and fluid overload with educating the patients about their diet being a cornerstone in avoiding decompensation [<xref ref-type="bibr" rid="scirp.68423-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.68423-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.68423-ref15">15</xref>] , this was only provided to 7.4% of the patients. Moreover screening for HCC per guidelines was only</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Multivariate adaptive regression splines (MARS) Model. Blue line training data, Red line testing data</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/68423x6.png"/></fig><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Study primary outcomes</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >N = 139</th></tr></thead><tr><td align="center" valign="middle" >Variceal Bleeding―n. (%)</td><td align="center" valign="middle" >37 (26.6)</td></tr><tr><td align="center" valign="middle" >PPI</td><td align="center" valign="middle" >35 (94.6)</td></tr><tr><td align="center" valign="middle" >Somatostatin Analogues</td><td align="center" valign="middle" >35 (94.6)</td></tr><tr><td align="center" valign="middle" >Antibiotic therapy for SBP prophylaxis</td><td align="center" valign="middle" >35 (94.6)</td></tr><tr><td align="center" valign="middle" >Ascites and Volume Overload―n. (%)</td><td align="center" valign="middle" >54 (38.9)</td></tr><tr><td align="center" valign="middle" >Diuretics</td><td align="center" valign="middle" >41 (75.9)</td></tr><tr><td align="center" valign="middle" >Salt Restriction</td><td align="center" valign="middle" >47 (87.0)</td></tr><tr><td align="center" valign="middle" >Patient Education</td><td align="center" valign="middle" >4 (7.4)</td></tr><tr><td align="center" valign="middle" >HCC screening―n. (%)<sup>*</sup></td><td align="center" valign="middle" >56 (40.3)</td></tr></tbody></table></table-wrap><p><sup>*</sup>Every 6 to 12 month; Abbreviations: PPI: Proton Pump Inhibitor; SBP: Spontaneous Bacterial Peritonitis.</p><p>40.3%. Acute medical management with proton pump inhibitors, somatostatin analogues and antibiotics for SBP prophylaxis for patients admitted with bleeding varices was optimal (94.6%).</p><p>The 30-day readmission rate was 31%. It is lower than what Volk et al. reported (37%) [<xref ref-type="bibr" rid="scirp.68423-ref12">12</xref>] , but higher than the study conducted by Berman et al. (20%) [<xref ref-type="bibr" rid="scirp.68423-ref17">17</xref>] . There are no current studies that show the national average of cirrhosis 30-day readmission rate.</p><p>This study shows another predictive role of MELD score; patients with a higher MELD score were found more likely to be readmitted; this was also reported by Berman et al. [<xref ref-type="bibr" rid="scirp.68423-ref17">17</xref>] .</p><p>Johnson et al. [<xref ref-type="bibr" rid="scirp.68423-ref8">8</xref>] has described several interventions to control some of the factors that may lead to re- hospitalization like providing an order set for variceal bleeding and patients’ education for patients with ascites.In his prospective cohort study, using an admission order set forvariceal bleeding and providing educational sessions for medical practitioners were associated with a statistically significant lower number of 30-day re- admissions rate (41% vs. 13%; P &lt; 0.001). However, there was no significant decrease in length of hospital stay</p><p>Shu et al. [<xref ref-type="bibr" rid="scirp.68423-ref18">18</xref>] reported that longer LOS was associated with a higher rate of 30-day readmission, our study showed the opposite where patients with shorter length of stay were found to be more likely readmitted within 30 days of discharge. This might indicate that these patients need optimal inpatient management before discharge.</p><p>Cirrhosis is a complex disease with multiple complications that are overwhelming for patients and their care providers. Our current episodic and uncoordinated system of healthcare delivery is poorly structured for such patients with chronic disease [<xref ref-type="bibr" rid="scirp.68423-ref19">19</xref>] . This study points out some breaches in managing these patients; and it may open a way for certain interventions to help optimize the care of LC patient.</p><p>The limitations of our study include: 1) It’s retrospective; 2) It was done in a single center; 3) The sample size is relatively small. Also re-admissions could have happened to other hospitals in the area.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In summary, compliance with AASLD guidelines was optimal for patients with variceal bleeding. Further optimization is required for HCC screening and patient education for ascites. We believe that this study will add to the literature in several ways. First, it helps identifying gaps in treating patients with LC. Second, it outlines predictors of 30-day readmission that can help identifying patients that might benefit from post discharge care. Further prospective studies are needed to better identify and possibly implement quality measures that might improve patients’ outcome and avoid unnecessary hospitalizations.</p></sec><sec id="s6"><title>Cite this paper</title><p>Maen M. Masadeh,Ali Zaied,Feroze Hussain,Heidi Spratt,Roger Soloway, (2015) Adherence to American Association for the Study of Liver Diseases (AASLD) Guidelines and Predictors of Readmission in Cirrhotic Patients: A Single Center Experience. Open Access Library Journal,02,1-8. doi: 10.4236/oalib.1101593</p></sec><sec id="s7"><title>Abbreviations</title><p>LC: Liver cirrhosis</p><p>AASLD: American Association for the Study of Liver Disease</p><p>VB: Variceal Bleeding</p><p>HCC: Hepatocellular Carcinoma</p><p>HE: Hepatic Encephalopathy</p><p>SBP: Spontaneous Bacterial peritonitis</p><p>MELD: Model for End Stage Liver Disease</p><p>MARS: Multivariate Adaptive Regression Splines</p><p>LOS: Length of Stay</p><p>CT: Computed Tomography</p><p>MRI: Magnetic Resonance Imaging</p></sec><sec id="s8"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.68423-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">CDC/NCHS. National Hospital Discharge Survey (2010) Detailed Diagnosis and Procedure Tables; Number of First-Listed Diagnoses for Discharges from Short-Stay Hospitals, by ICD-9-CM Code, Sex, Age, and Geographic Region.</mixed-citation></ref><ref id="scirp.68423-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Murphy, S., Xu, J. and Kochanek, K. (2013) Deaths: Final Data for 2010. National Vital Statistics Reports, 61, 1-118.</mixed-citation></ref><ref id="scirp.68423-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Schuppan, D. and Afdhal, N.H. (2008) Liver Cirrhosis. The Lancet, 371, 838-851. http://dx.doi.org/10.1016/S0140-6736(08)60383-9</mixed-citation></ref><ref id="scirp.68423-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Martínez-Noguera, A., Montserrat, E., Torrubia, S. and Villalba, J. (2002) Doppler in Hepatic Cirrhosis and Chronic Hepatitis. Seminars in Ultrasound, CT and MRI, 23, 19-36. http://dx.doi.org/10.1016/S0887-2171(02)90027-2</mixed-citation></ref><ref id="scirp.68423-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gines, P., Quintero, E., Arroyo, V., et al. (1987) Compensated Cirrhosis: Natural History and Prognostic Factors. Hepatology (Baltimore, Md), 7, 122-128. http://dx.doi.org/10.1002/hep.1840070124</mixed-citation></ref><ref id="scirp.68423-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Runyon, B.A. (1994) Care of Patients with Ascites. The New England Journal of Medicine, 330, 337-342. http://dx.doi.org/10.1056/NEJM199402033300508</mixed-citation></ref><ref id="scirp.68423-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Runyon, B.A. (2015) Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th Edition, Saunders, Philadelphia, PA, Chapter 93, 1553.e5-1576.e5.</mixed-citation></ref><ref id="scirp.68423-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Johnson, E.A., Spier, B.J., Leff, J.A., Lucey, M.R. and Said, A. (2011) Optimising the Care of Patients with Cirrhosis and Gastrointestinal Haemorrhage: A Quality Improvement Study. Alimentary Pharmacology &amp; Therapeutics, 34, 76-82. http://dx.doi.org/10.1111/j.1365-2036.2011.04692.x</mixed-citation></ref><ref id="scirp.68423-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Tsao, G. and Bosch, J. (2010) Management of Varices and Variceal Hemorrhage in Cirrhosis. The New England Journal of Medicine, 362, 823-832. http://dx.doi.org/10.1056/NEJMra0901512</mixed-citation></ref><ref id="scirp.68423-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">El-Serag, H.B. and Mason, A.C. (1999) Rising Incidence of Hepatocellular Carcinoma in the United States. The New England Journal of Medicine, 340, 745-750. http://dx.doi.org/10.1056/NEJM199903113401001</mixed-citation></ref><ref id="scirp.68423-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, B.H., Yang, B.H. and Tang, Z.Y. (2004) Randomized Controlled Trial of Screening for Hepatocellular Carcinoma. Journal of Cancer Research and Clinical Oncology, 130, 417-422. http://dx.doi.org/10.1007/s00432-004-0552-0</mixed-citation></ref><ref id="scirp.68423-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Volk, M.L., Tocco, R.S., Bazick, J., Rakoski, M.O. and Lok, A.S. (2012) Hospital Readmissions among Patients with Decompensated Cirrhosis. The American Journal of Gastroenterology, 107, 247-252. http://dx.doi.org/10.1038/ajg.2011.314</mixed-citation></ref><ref id="scirp.68423-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Tsao, G., Sanyal, A.J., Grace, N.D. and Carey, W. (2007) Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. Hepatology (Baltimore, Md), 46, 922-938. http://dx.doi.org/10.1002/hep.21907</mixed-citation></ref><ref id="scirp.68423-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N. and Conde, J.G. (2009) Research Electronic Data Capture (REDCap)—A Metadata-Driven Methodology and Workflow Process for Providing Translational Research Informatics Support. Journal of Biomedical Informatics, 42, 377-381. http://dx.doi.org/10.1016/j.jbi.2008.08.010</mixed-citation></ref><ref id="scirp.68423-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Runyon, B.A. (2009) Management of Adult Patients with Ascites Due to Cirrhosis: An Update. Hepatology (Baltimore, Md), 49, 2087-2107. http://dx.doi.org/10.1002/hep.22853</mixed-citation></ref><ref id="scirp.68423-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Bruix, J. and Sherman, M., American Association for the Study of Liver D (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology (Baltimore, Md), 53, 1020-1022. http://dx.doi.org/10.1002/hep.24199</mixed-citation></ref><ref id="scirp.68423-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Berman, K., Tandra, S., Forssell, K., et al. (2011) Incidence and Predictors of 30-Day Readmission among Patients Hospitalized for Advanced Liver Disease. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 9, 254-259. http://dx.doi.org/10.1016/j.cgh.2010.10.035</mixed-citation></ref><ref id="scirp.68423-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Shu, C.C., Lin, Y.F., Hsu, N.C. and Ko, W.J. (2012) Risk Factors for 30-Day Readmission in General Medical Patients Admitted from the Emergency Department: A Single Centre Study. Internal Medicine Journal, 42, 677-682. http://dx.doi.org/10.1111/j.1445-5994.2011.02562.x</mixed-citation></ref><ref id="scirp.68423-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Volk, M.L., Piette, J.D., Singal, A.S. and Lok, A.S. (2010) Chronic Disease Management for Patients with Cirrhosis. Gastroenterology, 139, 14e1-16e1.</mixed-citation></ref></ref-list></back></article>